vs
Fortive（FTV）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
Fortive的季度营收约是MESA LABORATORIES INC的2.1倍（$139.0M vs $65.1M）。Fortive净利率更高（133.6% vs 5.6%，领先128.0%）。MESA LABORATORIES INC同比增速更快（3.6% vs -91.4%）。Fortive自由现金流更多（$335.5M vs $18.0M）。过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -69.8%）
Fortive是总部位于美国华盛顿州埃弗里特的工业科技集团，专注于提供互联工作流解决方案所需的核心技术，研发、生产及销售专业工程类产品、软件与服务，旗下业务分为智能运营解决方案、精密技术、先进医疗解决方案三大战略板块。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
FTV vs MLAB — 直观对比
营收规模更大
FTV
是对方的2.1倍
$65.1M
营收增速更快
MLAB
高出95.1%
-91.4%
净利率更高
FTV
高出128.0%
5.6%
自由现金流更多
FTV
多$317.5M
$18.0M
两年增速更快
MLAB
近两年复合增速
-69.8%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $139.0M | $65.1M |
| 净利润 | $185.7M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | 75.4% | 12.2% |
| 净利率 | 133.6% | 5.6% |
| 营收同比 | -91.4% | 3.6% |
| 净利润同比 | -11.1% | 316.6% |
| 每股收益（稀释后） | $0.58 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FTVMLAB
| Q4 25 | $139.0M | $65.1M | ||
| Q3 25 | $1.0B | $60.7M | ||
| Q2 25 | $1.5B | $59.5M | ||
| Q1 25 | $1.5B | $62.1M | ||
| Q4 24 | $1.6B | $62.8M | ||
| Q3 24 | $1.5B | $57.8M | ||
| Q2 24 | $1.6B | $58.2M | ||
| Q1 24 | $1.5B | $58.9M |
净利润FTVMLAB
| Q4 25 | $185.7M | $3.6M | ||
| Q3 25 | $55.0M | $2.5M | ||
| Q2 25 | $166.6M | $4.7M | ||
| Q1 25 | $171.9M | $-7.1M | ||
| Q4 24 | $208.8M | $-1.7M | ||
| Q3 24 | $221.6M | $3.4M | ||
| Q2 24 | $195.1M | $3.4M | ||
| Q1 24 | $207.4M | $-254.6M |
毛利率FTVMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | 63.2% | 61.5% | ||
| Q2 25 | 59.0% | 62.0% | ||
| Q1 25 | 59.8% | 61.8% | ||
| Q4 24 | 60.3% | 63.3% | ||
| Q3 24 | 60.0% | 61.3% | ||
| Q2 24 | 59.8% | 64.0% | ||
| Q1 24 | 59.3% | 62.1% |
营业利润率FTVMLAB
| Q4 25 | 75.4% | 12.2% | ||
| Q3 25 | 15.5% | 7.8% | ||
| Q2 25 | 14.6% | 5.1% | ||
| Q1 25 | 15.8% | 2.4% | ||
| Q4 24 | 19.0% | 9.2% | ||
| Q3 24 | 19.3% | 6.1% | ||
| Q2 24 | 19.4% | 9.6% | ||
| Q1 24 | 19.8% | -460.6% |
净利率FTVMLAB
| Q4 25 | 133.6% | 5.6% | ||
| Q3 25 | 5.4% | 4.1% | ||
| Q2 25 | 11.0% | 8.0% | ||
| Q1 25 | 11.7% | -11.4% | ||
| Q4 24 | 12.9% | -2.7% | ||
| Q3 24 | 14.4% | 5.9% | ||
| Q2 24 | 12.6% | 5.8% | ||
| Q1 24 | 13.6% | -432.2% |
每股收益（稀释后）FTVMLAB
| Q4 25 | $0.58 | $0.65 | ||
| Q3 25 | $0.16 | $0.45 | ||
| Q2 25 | $0.49 | $0.85 | ||
| Q1 25 | $0.50 | $-1.30 | ||
| Q4 24 | $0.60 | $-0.31 | ||
| Q3 24 | $0.63 | $0.63 | ||
| Q2 24 | $0.55 | $0.62 | ||
| Q1 24 | $0.58 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $375.5M | $29.0M |
| 总债务越低越好 | $3.2B | $68.4M |
| 股东权益账面价值 | $6.5B | $186.7M |
| 总资产 | $11.7B | $434.8M |
| 负债/权益比越低杠杆越低 | 0.50× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资FTVMLAB
| Q4 25 | $375.5M | $29.0M | ||
| Q3 25 | $430.8M | $20.4M | ||
| Q2 25 | $1.8B | $21.3M | ||
| Q1 25 | $892.1M | $27.3M | ||
| Q4 24 | $813.3M | $27.3M | ||
| Q3 24 | $811.3M | $24.3M | ||
| Q2 24 | $644.1M | $28.5M | ||
| Q1 24 | $704.6M | $28.2M |
总债务FTVMLAB
| Q4 25 | $3.2B | $68.4M | ||
| Q3 25 | $3.3B | $69.4M | ||
| Q2 25 | $4.8B | $70.3M | ||
| Q1 25 | $3.9B | $71.3M | ||
| Q4 24 | $3.7B | $72.2M | ||
| Q3 24 | $3.9B | $73.1M | ||
| Q2 24 | $3.8B | $74.1M | ||
| Q1 24 | $3.9B | — |
股东权益FTVMLAB
| Q4 25 | $6.5B | $186.7M | ||
| Q3 25 | $6.5B | $178.5M | ||
| Q2 25 | $10.4B | $172.5M | ||
| Q1 25 | $10.2B | $159.8M | ||
| Q4 24 | $10.2B | $155.2M | ||
| Q3 24 | $10.6B | $161.5M | ||
| Q2 24 | $10.5B | $150.7M | ||
| Q1 24 | $10.5B | $145.4M |
总资产FTVMLAB
| Q4 25 | $11.7B | $434.8M | ||
| Q3 25 | $11.9B | $430.4M | ||
| Q2 25 | $18.2B | $435.7M | ||
| Q1 25 | $17.1B | $433.3M | ||
| Q4 24 | $17.0B | $433.3M | ||
| Q3 24 | $17.5B | $454.1M | ||
| Q2 24 | $17.3B | $440.4M | ||
| Q1 24 | $17.5B | $446.8M |
负债/权益比FTVMLAB
| Q4 25 | 0.50× | 0.37× | ||
| Q3 25 | 0.51× | 0.39× | ||
| Q2 25 | 0.46× | 0.41× | ||
| Q1 25 | 0.38× | 0.45× | ||
| Q4 24 | 0.36× | 0.47× | ||
| Q3 24 | 0.37× | 0.45× | ||
| Q2 24 | 0.36× | 0.49× | ||
| Q1 24 | 0.38× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $365.9M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $335.5M | $18.0M |
| 自由现金流率自由现金流/营收 | 241.4% | 27.7% |
| 资本支出强度资本支出/营收 | 21.9% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.97× | 5.17× |
| 过去12个月自由现金流最近4个季度 | $978.1M | $37.9M |
8季度趋势，按日历期对齐
经营现金流FTVMLAB
| Q4 25 | $365.9M | $18.8M | ||
| Q3 25 | $164.4M | $8.2M | ||
| Q2 25 | $311.2M | $1.9M | ||
| Q1 25 | $241.7M | $12.7M | ||
| Q4 24 | $502.2M | $18.1M | ||
| Q3 24 | $459.0M | $5.3M | ||
| Q2 24 | $308.9M | $10.7M | ||
| Q1 24 | $256.7M | $12.9M |
自由现金流FTVMLAB
| Q4 25 | $335.5M | $18.0M | ||
| Q3 25 | $153.1M | $7.1M | ||
| Q2 25 | $274.5M | $884.0K | ||
| Q1 25 | $215.0M | $11.9M | ||
| Q4 24 | $465.2M | $17.3M | ||
| Q3 24 | $431.2M | $3.5M | ||
| Q2 24 | $279.7M | $9.9M | ||
| Q1 24 | $230.3M | $12.3M |
自由现金流率FTVMLAB
| Q4 25 | 241.4% | 27.7% | ||
| Q3 25 | 14.9% | 11.7% | ||
| Q2 25 | 18.1% | 1.5% | ||
| Q1 25 | 14.6% | 19.2% | ||
| Q4 24 | 28.7% | 27.6% | ||
| Q3 24 | 28.1% | 6.0% | ||
| Q2 24 | 18.0% | 16.9% | ||
| Q1 24 | 15.1% | 21.0% |
资本支出强度FTVMLAB
| Q4 25 | 21.9% | 1.1% | ||
| Q3 25 | 1.1% | 1.8% | ||
| Q2 25 | 2.4% | 1.7% | ||
| Q1 25 | 1.8% | 1.2% | ||
| Q4 24 | 2.3% | 1.3% | ||
| Q3 24 | 1.8% | 3.1% | ||
| Q2 24 | 1.9% | 1.5% | ||
| Q1 24 | 1.7% | 0.9% |
现金转化率FTVMLAB
| Q4 25 | 1.97× | 5.17× | ||
| Q3 25 | 2.99× | 3.32× | ||
| Q2 25 | 1.87× | 0.40× | ||
| Q1 25 | 1.41× | — | ||
| Q4 24 | 2.41× | — | ||
| Q3 24 | 2.07× | 1.54× | ||
| Q2 24 | 1.58× | 3.17× | ||
| Q1 24 | 1.24× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FTV
| Services | $137.9M | 99% |
| Products | $1.1M | 1% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
